Participated · Series A · Aug 2024

Noetik is an AI-native biotechnology company that combines self-supervised machine learning with high-throughput spatial omics and in vivo CRISPR perturbation to discover precision cancer therapies. Its discovery platform pairs human multimodal spatial omics data purpose-built for machine learning with a massively multiplexed in vivo CRISPR Perturb-Map system to train foundation models of tissue and tumor biology. The company has built one of the world’s largest spatial omics-based atlases of human cancer biology and trains multi-modal cancer foundation models such as OCTO. Proceeds from the recent Series A will be used to expand the atlas, scale Perturb-Map throughput, and increase training of its models. Noetik plans to leverage these platform capabilities to advance an innovative pipeline of cancer therapeutics candidates into the clinic and to establish strategic partnerships with academic institutions, health care providers, and pharmaceutical companies. The company is based in San Francisco and recently appointed Shafique Virani as Chief Business Officer to lead partnering efforts. Noetik has built a multimodal tissue profiling platform that combines self-supervised learning with spatial biology to address fundamental problems in cancer immunology. In under 12 months of operations the company has generated hundreds of terabytes of human data across genomics, transcriptomics, and proteomics to enable foundation models for cell and tissue biology. The company plans to use transformer-based machine learning methods applied to this internal data stack to accelerate target and therapeutics discovery. The recent funding will support substantial internal data generation efforts and continued development of those ML methods. Proceeds will also be used to expand Noetik’s team in machine learning, computational biology, and cancer immunology. Noetik is based in San Francisco and is led by CEO Ron Alfa, with founding leaders including CTO Lacey Padron and CSO Jacob Rinaldi.